Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
about
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsBeyond hypomethylating agents failure in patients with myelodysplastic syndromesSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyClinical Results of Hypomethylating Agents in AML TreatmentOutcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Bridging-to-transplant with Azacitidine for Myelodysplastic Syndrome and Acute Myeloid Leukemia, Reduces the Incidence of Acute Graft-versus-host Disease.Epigenetic therapies in MDS and AMLMulticenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: BloodFive-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia.Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Transplantation for myelodysplastic syndromes 2013.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.5-Azacytidine for the treatment of myelodysplastic syndromes.When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.Update on the pharmacotherapy for myelodysplastic syndromes.Stopping higher-risk myelodysplastic syndrome in its tracks.Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantationResponse to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.How I treat acute myeloid leukemia presenting with preexisting comorbidities.Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.A paediatric case of successful non-myeloablative bone marrow transplantation after azacitidine therapy for non-Down syndrome acute megakaryoblastic leukaemia with monosomy 7.The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS.Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
P2860
Q24605618-7B0F1FB3-2C75-4D6A-B7A1-6B27953A1215Q26827079-ECFDDF15-FDEB-4203-AC9C-7D2AA824DF9AQ27010653-388853AD-ABEF-4C97-B521-E03A34BDE2A1Q27022725-0BDB6E98-DF8A-4FE1-987E-E9F1737BF2E6Q30252975-D54EC9C7-E9D7-4989-9BE3-F2FCAAE4C37CQ30884173-56A8EC86-FF60-4122-A11A-C6731CBCC69AQ33815617-2FBACF80-5D28-45CD-87FD-9F95058A9C3BQ33863567-47BCBAE0-C3B1-4986-AC5D-104C48EFCA2AQ34217884-D500DF44-EB77-4DCB-966A-E4CC05417E2BQ36339459-3B28CCB9-36E0-41C6-80D1-FCE4238CEC45Q36431041-A87A602B-6E99-4CE8-A3BF-80668FB9FB67Q36789428-FF56A038-61F1-4F0E-89DA-982102DEBC1FQ36806501-0F1297D5-7AEE-4697-9DED-B2777817009CQ36890784-D3CF04D7-67DE-4939-9E57-A9E8F9704375Q37263146-F3709B86-C08E-48F8-95B9-FAA4BF70AFCBQ37600407-C545AE7F-35B4-49E5-98D3-1D842ADAF39FQ37707098-A632BF95-F5A1-4B9F-A4E6-1B00653C74EEQ38102062-C51991AA-2072-4BD0-81D4-5A5FC184A741Q38132814-85AFBD5D-AAFF-42D6-ABFA-75C77309731DQ38160051-0C031AF2-F28C-4431-974E-F3930DF8C818Q38172875-65BDD98F-E625-437C-9DB1-D7A6232E8DEAQ38235662-3B91C23F-BD0F-4C0E-989A-4E3950BB1E08Q38248180-E49BEDCA-8C21-4FD4-8BCF-F056A6D1FEB9Q38540859-A62936F8-FA74-409C-B682-8E861C9C2ECCQ38540862-CC4BAC2C-71EF-4856-B85C-92AF700271C4Q38570399-2629FAF8-946C-456D-8A89-E69D4622C18BQ38860919-6B0500E4-FCCF-4946-80AA-4C193FC835A6Q39092515-DFF65260-CE77-45B0-A696-5602436CCAC8Q39307476-D5B4588E-C9F0-4B1F-B6EF-40561130C48FQ39474990-631CE80A-98A4-49C1-BB55-BC8B22D78D42Q39527812-5149D37A-DAFB-4577-BCFC-9F40594A0151Q39575152-EBCC9279-C68D-4924-A530-CD8F50676F79Q41107043-E74CAFDF-0D58-4FB0-A133-A31482B2AA44Q41359251-D68E8403-DE3B-442F-9227-1283B42B6216Q47987764-D7851AA7-C155-45D4-B24E-2A7FFEBACAA2Q52897534-F4169672-CF06-41F2-989A-7B5C9267CAEEQ52901403-2DE38976-9157-45CD-B440-868F8E4F0056Q54392826-765F1FF1-E8F9-416F-A369-213DCE8A03B7
P2860
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pretransplantation therapy wit ...... outcome in patients with MDS.
@ast
Pretransplantation therapy wit ...... outcome in patients with MDS.
@en
type
label
Pretransplantation therapy wit ...... outcome in patients with MDS.
@ast
Pretransplantation therapy wit ...... outcome in patients with MDS.
@en
prefLabel
Pretransplantation therapy wit ...... outcome in patients with MDS.
@ast
Pretransplantation therapy wit ...... outcome in patients with MDS.
@en
P2093
P2860
P1476
Pretransplantation therapy wit ...... outcome in patients with MDS.
@en
P2093
Aaron T Gerds
Bart L Scott
Elihu H Estey
Ted A Gooley
P2860
P304
P356
10.1016/J.BBMT.2012.01.009
P577
2012-01-16T00:00:00Z